PRTK - Paratek Offers Long-Term Value Potential In The Difficult Antibiotic Business

• Paratek's new broad-spectrum antibiotic Nuzyra has shown good uptake so far in the hospital setting, and the company is starting to try to break into primary care as well.
• Paratek has further upside potential based on its contract with BARDA for anthrax treatment and prevention, as well as from its developmental indication in NTM treatment.
• Paratek looks like it has a good long-term value proposition although the failures of several recent antibiotic companies should serve as a cautionary tale.

For further details see: